Literature DB >> 14523551

Immunology and functional genomics of Behçet's disease.

M Zierhut1, N Mizuki, S Ohno, H Inoko, A Gül, K Onoé, E Isogai.   

Abstract

Behçet's disease (BD) is a multisystemic inflammatory disorder. Although the cause and pathogenesis of BD are still unclear, there is evidence for genetic, immunologic and infectious factors at the onset or in the course of BD. This review focuses on the functional genomics and immunology of BD. HLA-B51 is the major disease susceptibility gene locus in BD. An increased number of gammadelta T cells in the peripheral blood and in the involved tissues have been reported. However, the T cells at the sites of inflammation appear to be a phenotypically distinct subset. There is also a significant gammadelta T cell proliferative response to mycobacterial 65-kDa heat shock protein peptides. Homologous peptides derived from the human 60-kDa heat shock protein were observed in BD patients. There is evidence that natural killer T cells may also play a role in BD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14523551     DOI: 10.1007/s00018-003-2333-3

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  30 in total

1.  Excessive expression of Txk, a member of the Tec family of tyrosine kinases, contributes to excessive Th1 cytokine production by T lymphocytes in patients with Behcet's disease.

Authors:  H Nagafuchi; M Takeno; H Yoshikawa; M S Kurokawa; K Nara; E Takada; C Masuda; M Mizoguchi; N Suzuki
Journal:  Clin Exp Immunol       Date:  2005-02       Impact factor: 4.330

Review 2.  Standard and novel therapeutic approaches to Behçet's disease.

Authors:  Ahmet Gul
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  HLA-B51 gene and its expression in association with Behçet's Disease in Denizli Province of Turkey.

Authors:  Ayfer Atalay; Sanem Yildiz-Demirtepe; Sinan Tatlipinar; Berna Sanli-Erdoğan; Veli Cobankara; Cem Yildirim; Hüseyin Bağci; Erol Omer Atalay
Journal:  Mol Biol Rep       Date:  2007-06-27       Impact factor: 2.316

Review 4.  Clinical Immunology Review Series: an approach to the patient with recurrent orogenital ulceration, including Behçet's syndrome.

Authors:  M T Keogan
Journal:  Clin Exp Immunol       Date:  2008-12-11       Impact factor: 4.330

5.  Clinical response to thalidomide and colchicine in two siblings with Behcet's disease carrying a single mutated MEFV allele.

Authors:  Donato Rigante; Francesco La Torre; Giuseppina Calcagno; Fernanda Falcini
Journal:  Rheumatol Int       Date:  2011-07-22       Impact factor: 2.631

Review 6.  Immunopathogenesis of Behçet's disease with special emphasize on the possible role of antigen presenting cells.

Authors:  Salih Pay; Ismail Simşek; Hakan Erdem; Ayhan Dinç
Journal:  Rheumatol Int       Date:  2007-03       Impact factor: 2.631

7.  Correlation between IL-17A/F, IL-23, IL-35 and IL-12/-23 (p40) levels in peripheral blood lymphocyte cultures and disease activity in Behcet's patients.

Authors:  Cemile Sonmez; Aysegul Atak Yucel; Turan Hilmi Yesil; Hamit Kucuk; Berna Sezgin; Ridvan Mercan; Ahmet Eftal Yucel; Gulderen Yanikkaya Demirel
Journal:  Clin Rheumatol       Date:  2018-03-20       Impact factor: 2.980

8.  Association of TNFA promoter region haplotype in Behçet's Disease.

Authors:  KyungSook Park; NaYoung Kim; JungHyun Nam; Dongsik Bang; Eun-So Lee
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

9.  Enhanced NLRP3 and DEFA1B Expression During the Active Stage of Parenchymal Neuro-Behçet's Disease.

Authors:  Elif Ugurel; Ece Erdag; Cem Ismail Kucukali; Ayca Olcay; Elif Sanli; Ece Akbayir; Murat Kurtuncu; Tuncay Gunduz; Vuslat Yilmaz; Erdem Tuzun; Burcak Vural
Journal:  In Vivo       Date:  2019 Sep-Oct       Impact factor: 2.155

10.  Paradoxical mucocutaneous flare in a case of Behçet's disease treated with tocilizumab.

Authors:  Luca Cantarini; Giuseppe Lopalco; Antonio Vitale; Laura Coladonato; Donato Rigante; Orso Maria Lucherini; Giovanni Lapadula; Florenzo Iannone
Journal:  Clin Rheumatol       Date:  2014-04-15       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.